Abstract 36P
Background
Survival in patients with contralateral breast cancer Kamishov S.V., Izrailbekova K.Sh. Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan, Tashkent. Survival data are not readily available in many developing countries due to inadequate information systems to collect reliable data on cancer mortality. Not all cancer patients die from cancer. Thus, cancer and other causes of death act independently or simultaneously. A cohort study was conducted to identify risk factors for contralateral breast cancer and to determine whether there was any significant difference in survival among patients with unilateral breast cancer (UBC) and patients with primary contralateral breast cancer (PCBC).
Methods
The study group consisted of patients with breast carcinoma as the first invasive primary cancer, diagnosed in 2012-2019 (n = 3492) at the Republican Special Medical Center for Medical and Rehabilitation of Uzbekistan, Tashkent). They were under surveillance until December 31, 2019. All patients undergoing treatment are monitored in accordance with the observation protocols of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan In this study, the follow-up loss was 10% in UBC patients and 7.5% in PCBC patients.
Results
A total of 3492 cases of breast cancer were diagnosed at the RSPMCHR from 2012-2019. The analysis included all patients with UBC who did not develop a second cancer (n = 3163) and patients with PCBC who developed contralateral breast cancer (n = 67). The relative survival rates between younger, middle-aged, and older women with PCBC were significantly different from each other (p = 0.001). The differences in the relative survival rates of young, middle-aged and older women with UBC were not statistically significant (p = 0.4).
Conclusions
Despite the small sample size, the present study shows that early diagnosis has a survival advantage in breast cancer. In addition to organizing mammographic screening, in developing countries, educational programs are needed to raise awareness of cancer in order to detect breast cancer at an early stage and reduce mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan, Tashkent.
Funding
Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan, Tashkent.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session